Companies › MiNK Therapeutics
1 active drug program in 3 registered trials: 3 Phase 2; Oncology, Respiratory; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| agenT-797 Innate lymphoid cell (ILC) therapy | – | Phase 2 | Pneumonia; Metastatic Esophageal Carcinoma; Colorectal Cancer Metastatic | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07615010 | agenT-797 | Phase 2 | Pneumonia | Respiratory | Jun 2027 |
| NCT06251973 | agenT-797 | Phase 2 | Metastatic Esophageal Carcinoma | Oncology | Aug 2027 |
| NCT07550088 | agenT-797 | Phase 2 | Colorectal Cancer Metastatic | Oncology | Sep 2028 |
Cash of $9m on 2026-06-30; operating cash outflow about $8m a year; runway about 14 months at that burn, to Aug 2027; 2 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
SPARK Biopharma NuvOx Allarity Therapeutics Rein Therapeutics CNS Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.